Merck’s (NYSE:MRK) monoclonal antibody clesrovimab, designed as a prophylactic against respiratory syncytial virus (RSV), has ...

RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren ...

Cold and flu season — otherwise known as mid-October — is upon us. But this year, several advancements in vaccines could help ...

The effectiveness of the long-acting monoclonal antibody nirsevimab (Beyfortus) against primary care visits for lower ...

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

WellSpan Ephrata Community Hospital is now offering respiratory syncytial virus immunizations to infants born at the hospital ...

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in young children due to respiratory complications such as bronchiolitis and pneumonia. Yet little is understood about why ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

Clinician-scientists analyzed samples from patients' airways and blood, finding distinct changes in children with severe cases of RSV, including an increase in the number of natural killer (NK) cells ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

MOBILE, Ala. (WKRG) — More RSV cases are being reported in Mobile. It’s something you may not think much about unless you ...

First discovered in chimpanzees in 1956 and in children the following year, respiratory syncytial virus (RSV) isn’t new. Neither is it uncommon among the youngest and oldest populations ...